Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States
Parikh RB, Takvorian SU, Vader D, Wileyto E, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Shulman LN, Mamtani R, Hubbard RA, Investigators T. Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. Journal Of The National Cancer Institute 2021, 114: 571-578. PMID: 34893865, PMCID: PMC9002283, DOI: 10.1093/jnci/djab225.Peer-Reviewed Original ResearchConceptsMetastatic solid cancersFirst-line systemic therapyTreatment initiationSolid cancersSystemic therapyTreatment patternsMyelosuppressive therapyTreatment selectionCommunity-based oncology practicesCOVID-19 pandemicTechnology-enabled abstractionDays of diagnosisLife-threatening conditionInterrupted time series analysisMetastatic diagnosisUS patientsEffect modificationOncology practiceMetastatic cancerAdjusted probabilityPatientsPandemic periodPandemic-related delaysTherapyCancerRacial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database
Calip G, Ascha M, Wang X, Pierre A, Maignan K, Wadé N, Leng S, Seymour E, Chiu B, Sweiss K, Patel P, Neparidze N. Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database. Blood 2021, 138: 4121. DOI: 10.1182/blood-2021-152774.Peer-Reviewed Original ResearchReal-world progression-free survivalHigh-risk cytogenetic abnormalitiesCurrent equity holderFlatiron HealthBlack patientsWhite patientsMultiple myelomaMM patientsCytogenetic abnormalitiesClinical characteristicsHazard ratioAge groupsAutologous stem cell transplantationAdvisory CommitteeAdult MM patientsCytogenetic risk stratificationOlder black patientsTechnology-enabled abstractionYoung black patientsAdjusted hazard ratioRetrospective cohort studyFirst-line therapyFirst-line treatmentHigh-risk subsetProgression-free survival